Applied DNA Sciences, Inc. has announced a significant follow-on order valued at over $600,000 from a global in vitro diagnostics manufacturer. This order, the seventh of its kind, is for a multi-gram quantity of LineaDNA™, which is integral to a cancer diagnostic test. The agreement marks a continuation of a long-standing supply relationship, with scheduled deliveries set to commence in the second quarter of fiscal 2026, ending March 31, 2026. Applied DNA is recognized for its leadership in synthetic DNA manufacturing, utilizing scalable PCR platforms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.